Article Text

Download PDFPDF
Original article
Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression

Footnotes

  • ADF and IAV contributed equally.

  • Contributors Study concept and design: ADF, IV, AAS, SP, GGK. Acquisition of data: ADF, IV, ML, SP, GGK. Analysis of data: ADF, IV, ML, SP, GGK. Interpretation of data: ADF, IV, AAS, ML, MGS, CB, SP, GGK. Drafting of the manuscript: ADF, IV, GGK. Critical revision of the manuscript for intellectual content: AAS, ML, MGS, CB, SP.

  • Funding This work was funded through a Canadian Institutes of Health Research Team Grant in Inflammation in Chronic Disease. Grant ID: THC –135231.

  • Competing interests MGS, AAS and GGK share a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent 62/555,397. 7 September 2017. GGK has served as a speaker for Janssen, AbbVie and Pfizer, and has received research support from Janssen, AbbVie, GlaxoSmithKline and Shire.

  • Ethics approval The Conjoint Health Research Ethics Board at the University of Calgary (ID: 24423) and the UK’s IMS Health Scientific Review Committee approved the study protocol (ID: 16THIN052).

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • ADF and IAV contributed equally.

  • Contributors Study concept and design: ADF, IV, AAS, SP, GGK. Acquisition of data: ADF, IV, ML, SP, GGK. Analysis of data: ADF, IV, ML, SP, GGK. Interpretation of data: ADF, IV, AAS, ML, MGS, CB, SP, GGK. Drafting of the manuscript: ADF, IV, GGK. Critical revision of the manuscript for intellectual content: AAS, ML, MGS, CB, SP.

  • Funding This work was funded through a Canadian Institutes of Health Research Team Grant in Inflammation in Chronic Disease. Grant ID: THC –135231.

  • Competing interests MGS, AAS and GGK share a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent 62/555,397. 7 September 2017. GGK has served as a speaker for Janssen, AbbVie and Pfizer, and has received research support from Janssen, AbbVie, GlaxoSmithKline and Shire.

  • Ethics approval The Conjoint Health Research Ethics Board at the University of Calgary (ID: 24423) and the UK’s IMS Health Scientific Review Committee approved the study protocol (ID: 16THIN052).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles